Multiple myeloma: open trials in Belgium

31 open trials have a site in Belgium. Registry data; only the trial team decides who can take part.

NCT07222761
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Ziekenhuis Aan De Stroom, Antwerp · Az St-Jan Brugge-Oostende A.V., Brugge · Ziekenhuis Oost-Limburg, Genk · UZ Brussel, Jette · CHC MontLégia, Liège · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-11-04
NCT04634552
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Antwerp University Hospital, Edegem · UZ Leuven, Leuven · Centre Hospitalier Universitaire de Liège, Liège · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-11-03
NCT05201781
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Trial Treatment · Phase 4 · Janssen Research & Development, LLC
Universitair Ziekenhuis Antwerpen, Edegem · Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven
Registry updated 2026-11-03
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Institut Jules Bordet, Anderlecht · Ziekenhuis Aan De Stroom, Antwerp · Universitair Ziekenhuis Gent, Gent · Algemeen Ziekenhuis Groeninge, Kortrijk · UZ Leuven, Leuven
Registry updated 2026-11-03
NCT05652335
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
Antwerp University Hospital, Edegem · Universitair Ziekenhuis Gent, Gent · CHU de Liège, Liège
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Antwerp · Genk · Ghent · Sint-Niklaas
Registry updated 2026-10-30
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Universitair Ziekenhuis Antwerpen, Edegem · Universitair Ziekenhuis Gent, Gent · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Az St-Jan Brugge-Oostende A.V., Brugge · Grand Hopital de Charleroi, Charleroi · Universitair Ziekenhuis Gent, Gent · UZ Brussel, Jette · Clinique Saint Pierre, Ottignies-Louvain-la-Neuve · Algemeen Ziekenhuis Delta, Roeselare · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-10-27
NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie
Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven · Centre Hospitalier Universitaire de Liège, Liège
Registry updated 2026-10-27
NCT03761108
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1/2 · Regeneron Pharmaceuticals
Ziekenhuis Aan De Stroom, Antwerp · Cliniques universitaires Saint-Luc, Brussels
Registry updated 2026-10-26
NCT07648264
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Trial Treatment · Phase 3 · CSL Behring
Universitair Ziekenhuis Antwerpen (Uza), Edegem · UZ Gent, Ghent · CHU de Liège, Liège · AZ Delta, Roeselare
Registry updated 2026-10-14
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
JESSA Ziekenhuis, Hasselt · Chu Helora, La Louvière · UZ Leuven, Leuven · Centre Hospitalier Universitaire de Liège, Liège · Algemeen Ziekenhuis Delta, Roeselare
Registry updated 2026-10-07
NCT05730036
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Ziekenhuis Aan De Stroom, Antwerp · AZ Delta, Roeselare
Registry updated 2026-10-07
NCT06918002
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Trial Treatment · Phase 3 · Intergroupe Francophone du Myelome
Institut Jules Bordet, Anderlecht · Grand Hopital de Charleroi, Charleroi · Centre Hospitalier Universitaire de Liège, Liège · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-09-30
NCT06477783
Study on the Clinical Efficacy of Teclistamab and Talquetamab
Research · Universitaire Ziekenhuizen KU Leuven
Imelda, Bonheiden · UCL - Saint Luc, Brussels · Institut Jules Bordet, Brussels · Grand Hopital de Charleroi, Charleroi · Universitair Ziekenhuis Antwerpen (Uza), Edegem · Universitair Ziekenhuis Gent (Uz Gent), Ghent · Algemeen Ziekenhuis Maria Middelares (AZMM), Ghent · JESSA Ziekenhuis, Hasselt · Epicura, Hornu · AZ Groeninge, Kortrijk · UZ Leuven Gasthuisberg, Leuven · CHU Liège, Liège · CHR Citadelle, Liège · CHU Ambroise Paré, Mons · AZ Delta, Roeselare · Vitaz, Sint-Niklaas · Chu Ucl Namur, Yvoir
Registry updated 2026-09-25
2023-510173-34-00
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Trial Treatment · Phase 3 · Lakefront Biotherapeutics
Antwerp University Hospital, Edegem · UZ Leuven, Leuven · Centre Hospitalier Universitaire de Liège, Liège · Algemeen Ziekenhuis Delta, Roeselare · Cliniques Universitaires Saint-Luc, Sint-Lambrechts-Woluwe
Registry updated 2026-09-11
2022-501811-14-00
[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma
Trial Treatment · Phase 1/2 · University Of Antwerp
Antwerp University Hospital, Edegem · Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven
Registry updated 2026-09-02
2023-503404-89-00
A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)
Trial Treatment · Phase 1 · Genentech Inc.
Universitair Ziekenhuis Gent, Gent · UZ Brussel, Jette
Registry updated 2026-08-24
NCT05020236
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Trial Treatment · Phase 3 · Pfizer
Grand Hopital de Charleroi, Charleroi · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-08-24
NCT06152575
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Trial Treatment · Phase 3 · Pfizer
Centre Hospitalier EPICURA, Boussu · Grand Hopital de Charleroi, Charleroi · UZ Gent, Gent · UZ Brussel, Jette · Clinique Saint Pierre, Ottignies-Louvain-la-Neuve · Algemeen Ziekenhuis Delta, Roeselare · CHR Verviers, Verviers · Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Yvoir
Registry updated 2026-08-24
2025-525105-20-00
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie Deutschland GmbH & Co. KG
Universitair Ziekenhuis Gent, Gent · UZ Leuven, Leuven · Centre Hospitalier Universitaire de Liège, Liège
Registry updated 2026-07-15
NCT06140524
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Trial Treatment · Phase 2 · Regeneron Pharmaceuticals
Ziekenhuis Aan De Stroom, Antwerp · Algemeen Ziekenhuis klina, Brasschaat · Az St-Jan Brugge-Oostende A.V., Brugge · AZ St.-Elisabeth Herentals vzw, Herentals · Emmaues, Mechelen · Algemeen Ziekenhuis Delta, Roeselare
Registry updated 2026-07-08
NCT07674498
Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma
Trial Treatment · Jules Bordet Institute
Institut Jules Bordet, Anderlecht · CHU Saint-Pierre, Brussels · institut roi albert II, Woluwe-Saint-Lambert
Registry updated 2026-06-29
NCT06988020
"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma
Trial Treatment · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Cliniques universitaires Saint-Luc, Brussels
Registry updated 2026-04-24
NCT06679101
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Trial Treatment · Phase 3 · GlaxoSmithKline
Algemeen Ziekenhuis Delta, Roeselare
Registry updated 2026-04-22

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error